![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mls Multimedia | ASE:MLS | Athens | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.57 | 0.565 | 0.638 | 0.00 | 01:00:00 |
RNS Number:2619P Medical Solutions PLC 02 September 2003 Immediate Release 2 September 2003 MEDICAL SOLUTIONS plc BOARD STRENGTHENED Medical Solutions plc ("the Company" or "Medical"), the cancer and pathology services group, today announces the following appointments to the Board. These changes take immediate effect Professor Karol Sikora (53), currently a Non-Executive Director of Medical, is appointed to the Executive Board as Chief Scientific Director. Professor Sikora joined Medical in April 2002, prior to which he held a number of senior research positions within the pharmaceutical industry. These posts included: Vice President of Global Clinical Research (Oncology) at Pharmacia Corporation; Deputy Director of Clinical Research for the Imperial Cancer Research Fund; Chief of the World Health Organisation and Clinical Director for Cancer Services at Hammersmith Hospital, London. Currently Professor Sikora is a Consultant to AstraZeneca; Special Adviser to HCA Healthcare, the leading provider of healthcare services in America; Visiting Professor of Cancer Medicine and honorary Consultant Oncologist at Imperial College School of Medicine, Hammersmith Hospital, London. Medical Solutions today also announces a second appointment - that of Dr Sue Foden (50) who joins Medical as a Non-Executive Director. Dr Foden has significant experience in the healthcare market having been Chief Executive of Cancer Research Campaign Technology Limited (1987-2000) and Cancer Research Ventures Limited (1998-2000). Dr Foden is currently a Venture Partner of Merlin Biosciences Limited, the specialist life science investor trust. As part of this role Dr Foden is a Director of Ardana Bioscience Limited; BioVex Limited; De Novo Pharmaceuticals Limited and PIramed Limited (all of whom Merlin Bioscience have an active investment in). Personally Dr Foden is a Director of the Institute of Cancer Research, Royal Cancer Hospital, London; Cascade Fund Management Limited; NESTech Fund Management Limited and Oxford Ancestors Limited, and is a member of the Wellcome Trust's Technology Transfer Strategy Panel. Commenting on the appointments, Charles Green, Chief Executive of Medical Solutions said, "We are delighted to announce these two appointments today, both of which add significant weight to our management team. Professor Sikora has already proved a great asset to the Board in his role as a Non-Executive and I am delighted that he has decided to become a full-time member of the team. I am also delighted that Dr Sue Foden has agreed to join Medical. She has immense experience and knowledge in the biotechnology and pharmaceutical markets and I very much look forward to working with Sue in driving Medical forward." For further information, please contact: Medical Solutions Charles Green, Chief Executive Officer Tel: +44 (0) 115 973 9010 Andy Longstaffe, Finance Director Beattie Financial Tel: +44 (0) 20 7398 3300 Mike Wort/ Ann-marie Wilkinson Notes to Editors: Medical Solutions plc provides world leading services and technology for cancer diagnosis and pathology, supporting the Healthcare, Pharmaceutical and Biotechnology sectors. The group has two major divisions. The Services Division has a range of services including Specialist Pathology, Biomaterials Resources and Expertise, and 5 Laboratories. These services are provided to the Pharma/Botech Industry worldwide and to Healthcare providers, both public and private. The Technology Divisions' range includes specialist imaging software for telemedicine, image analysis and quantitation, and the SurePath liquid based cytology (smear test) system. This division is also key in supporting its' Service divisions offerings to both the Drug Development market and the Healthcare market. The combination of world-renowned expertise, state of the art reference laboratory facilities and innovative imaging technology puts Medical in a unique position. This information is provided by RNS The company news service from the London Stock Exchange END BOALBMRTMMIMBFJ
1 Year Mls Multimedia Chart |
1 Month Mls Multimedia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions